Drug profile · INN
hyaluronidase
VITRAGAN
hyaluronidase (VITRAGAN) is a hyaluronic acid hydrolytic enzyme. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Drug details — hyaluronidase
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 20
- Programs
- 13
- Data quality
- 0.89
Quick answer
hyaluronidase (VITRAGAN) is a hyaluronic acid hydrolytic enzyme. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Hyaluronic acid hydrolytic enzyme
Primary target: Hyaluronic acid
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
- Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
- Hyaluronidase
- Pegvorhyaluronidase alfa
- Pembrolizumab (+) Berahyaluronidase alfa
- Recombinant human hyaluronidase + immune globulin intravenous
- PEGylated recombinant human hyaluronidase PH20
- Recombinant human hyaluronidase PH20 (rHuPH20)
- 1838-009
Related & competitor drugs
Related patents
-
US 12178860
Hyaluronidase enzyme formulations for high volume administration
granted -
US 11723959
Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
granted -
US 10898551
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 10328130
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
granted -
US 10286044
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 9677061
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 9677062
Hyaluronidase and factor VIII compositions
granted -
US 9562223
Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)
granted -
US 8772246
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8765685
Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
granted -
US 8450470
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8431380
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8431124
Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
granted -
CA 2851057
UTILISATION COMBINEE D'UN GLYCOSAMINOGLYCANE SULFATE ET D'UNE HYALURONIDASE POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII
granted -
US 8202517
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 7781397
Human plasma hyaluronidase
granted -
US 7767429
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 7148201
Use of human plasma hyaluronidase in cancer treatment
granted -
US 7105330
Human plasma hyaluronidase
granted -
US 6193963
Method of treating tumor-bearing patients with human plasma hyaluronidase
expired
Frequently asked questions
What is hyaluronidase?
hyaluronidase (VITRAGAN) is a hyaluronic acid hydrolytic enzyme. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for hyaluronidase?
VITRAGAN is a marketed brand name for hyaluronidase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hyaluronidase?
hyaluronidase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.